<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1703">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01992380</url>
  </required_header>
  <id_info>
    <org_study_id>18F-AV-1451-A03</org_study_id>
    <nct_id>NCT01992380</nct_id>
  </id_info>
  <brief_title>A Study of Flortaucipir PET in Healthy Volunteers and Cognitively Impaired Subjects</brief_title>
  <official_title>Test-Retest Reproducibility of 18F-AV-1451 Injection for Brain Imaging of Tau in Healthy Volunteers and Cognitively Impaired Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avid Radiopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avid Radiopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test if two flortaucipir PET scans up to 4 weeks apart in healthy volunteers,&#xD;
      MCI and AD subjects provide the same results.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 13, 2013</start_date>
  <completion_date type="Actual">May 30, 2014</completion_date>
  <primary_completion_date type="Actual">May 30, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Test-Retest Reproducibility</measure>
    <time_frame>80-100 minutes postdose</time_frame>
    <description>Evaluate test-retest reproducibility of flortaucipir for brain imaging of tau in healthy volunteers and subjects with cognitive impairment. Standard uptake value ratios (SUVRs) for each scan, normalized to the cerebellar crus. A combination volume of interest (VOI) = weighted average of parietal, temporal, and occipital regions was used. The protocol pre-specified that test-retest endpoint was to be calculated for the combined group of healthy volunteers and cognitively impaired subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Test-Retest Reproducibility</measure>
    <time_frame>110-130 minutes postdose</time_frame>
    <description>Evaluate test-retest reproducibility of 18F-AV-1451 for brain imaging of tau in healthy volunteers and subjects with cognitive impairment. Standard uptake value ratios (SUVRs) for each scan, normalized to the cerebellar crus. A combination volume of interest (VOI) = weighted average of parietal, temporal, and occipital regions was used. The protocol pre-specified that test-retest endpoint was to be calculated for the combined group of healthy volunteers and cognitively impaired subjects</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Healthy Volunteer Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy males or females 50 years or older with no evidence of cognitive impairment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MCI subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects 50 years or older with mild cognitive impairment (MCI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probable AD Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects 50 years or older with probable Alzheimer's Disease (AD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flortaucipir F18</intervention_name>
    <description>IV injection, 370 MBq (10 mCi), two doses up to four weeks apart</description>
    <arm_group_label>Healthy Volunteer Subjects</arm_group_label>
    <arm_group_label>MCI subjects</arm_group_label>
    <arm_group_label>Probable AD Subjects</arm_group_label>
    <other_name>[F18]T807</other_name>
    <other_name>18F-AV-1451</other_name>
    <other_name>Tauvid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Brain PET scan</intervention_name>
    <description>positron emission tomography (PET) scan of the brain at 80-100 and 110-130 minutes after injection</description>
    <arm_group_label>Healthy Volunteer Subjects</arm_group_label>
    <arm_group_label>MCI subjects</arm_group_label>
    <arm_group_label>Probable AD Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy Volunteers&#xD;
&#xD;
               -  Male or female subjects ≥ 50 years of age&#xD;
&#xD;
               -  Mini-mental state examination (MMSE) ≥ 29&#xD;
&#xD;
          -  MCI Subjects&#xD;
&#xD;
               -  Male or female subjects ≥ 50 years of age&#xD;
&#xD;
               -  MMSE ≥ 24&#xD;
&#xD;
               -  Have MCI consistent with National Institute on Aging-Alzheimer's Association&#xD;
                  (NIA-AA) working group's diagnostic guidelines for AD&#xD;
&#xD;
               -  Have a study partner that can report on subject's activities of daily living&#xD;
&#xD;
          -  Probable AD Subjects&#xD;
&#xD;
               -  Male or female subjects ≥ 50 years of age&#xD;
&#xD;
               -  MMSE &gt; 10&#xD;
&#xD;
               -  Meet clinical criteria for probable AD based on the NIA-AA working group's&#xD;
                  diagnostic guidelines for AD&#xD;
&#xD;
               -  Have a study partner that can report on subject's activities of daily living&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current clinically significant psychiatric disease&#xD;
&#xD;
          -  Evidence of structural brain abnormalities&#xD;
&#xD;
          -  Evidence of dementing illness other than AD&#xD;
&#xD;
          -  Current clinically significant cardiovascular disease or ECG abnormalities, or&#xD;
             additional risk factors for Torsades de Pointes&#xD;
&#xD;
          -  Current clinically significant infectious disease, endocrine or metabolic disease,&#xD;
             pulmonary, renal or hepatic impairment, or cancer&#xD;
&#xD;
          -  History of alcohol or substance abuse or dependence&#xD;
&#xD;
          -  Females of childbearing potential who are not surgically sterile, not refraining from&#xD;
             sexual activity or not using reliable methods of contraception&#xD;
&#xD;
          -  Have received or participated in a trial with investigational medications in the past&#xD;
             30 days&#xD;
&#xD;
          -  have had a non-study related radiopharmaceutical imaging or treatment procedure within&#xD;
             7 days prior to the study imaging session.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Chair</role>
    <affiliation>Avid Radiopharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Devous MD Sr, Joshi AD, Navitsky M, Southekal S, Pontecorvo MJ, Shen H, Lu M, Shankle WR, Seibyl JP, Marek K, Mintun MA. Test-Retest Reproducibility for the Tau PET Imaging Agent Flortaucipir F 18. J Nucl Med. 2018 Jun;59(6):937-943. doi: 10.2967/jnumed.117.200691. Epub 2017 Dec 28.</citation>
    <PMID>29284675</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 8, 2013</study_first_submitted>
  <study_first_submitted_qc>November 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <results_first_submitted>July 16, 2020</results_first_submitted>
  <results_first_submitted_qc>August 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 7, 2020</results_first_posted>
  <last_update_submitted>August 20, 2020</last_update_submitted>
  <last_update_submitted_qc>August 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment between Nov 2013 and May 2014</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Healthy Volunteer Subjects</title>
          <description>Healthy males or females 50 years or older with no evidence of cognitive impairment&#xD;
Flortaucipir F18: IV injection, 370 MBq (10 mCi), two doses up to four weeks apart&#xD;
Brain PET scan: positron emission tomography (PET) scan of the brain</description>
        </group>
        <group group_id="P2">
          <title>MCI Subjects</title>
          <description>Subjects 50 years or older with mild cognitive impairment (MCI)&#xD;
Flortaucipir F18: IV injection, 370 MBq (10 mCi), two doses up to four weeks apart&#xD;
Brain PET scan: positron emission tomography (PET) scan of the brain</description>
        </group>
        <group group_id="P3">
          <title>Probable AD Subjects</title>
          <description>Subjects 50 years or older with probable Alzheimer's Disease (AD)&#xD;
Flortaucipir F18: IV injection, 370 MBq (10 mCi), two doses up to four weeks apart&#xD;
Brain PET scan: positron emission tomography (PET) scan of the brain</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Volunteer Subjects</title>
          <description>Healthy males or females 50 years or older with no evidence of cognitive impairment&#xD;
Flortaucipir F18: IV injection, 370 MBq (10 mCi), two doses up to four weeks apart&#xD;
Brain PET scan: positron emission tomography (PET) scan of the brain</description>
        </group>
        <group group_id="B2">
          <title>MCI Subjects</title>
          <description>Subjects 50 years or older with mild cognitive impairment (MCI)&#xD;
Flortaucipir F18: IV injection, 370 MBq (10 mCi), two doses up to four weeks apart&#xD;
Brain PET scan: positron emission tomography (PET) scan of the brain</description>
        </group>
        <group group_id="B3">
          <title>Probable AD Subjects</title>
          <description>Subjects 50 years or older with probable Alzheimer's Disease (AD)&#xD;
Flortaucipir F18: IV injection, 370 MBq (10 mCi), two doses up to four weeks apart&#xD;
Brain PET scan: positron emission tomography (PET) scan of the brain</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.8" spread="9.5"/>
                    <measurement group_id="B2" value="70.3" spread="5.4"/>
                    <measurement group_id="B3" value="74.4" spread="7.3"/>
                    <measurement group_id="B4" value="70.1" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mini Mental Status Exam (MMSE)</title>
          <description>Mini-mental status exam (MMSE) is a 30-point questionnaire that is used to measure cognitive impairment. Scores range from 0 to 30 with lower scores representing greater levels of cognitive impairment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.7" spread="0.52"/>
                    <measurement group_id="B2" value="28.3" spread="1.58"/>
                    <measurement group_id="B3" value="23.9" spread="4.58"/>
                    <measurement group_id="B4" value="26.8" spread="3.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Test-Retest Reproducibility</title>
        <description>Evaluate test-retest reproducibility of flortaucipir for brain imaging of tau in healthy volunteers and subjects with cognitive impairment. Standard uptake value ratios (SUVRs) for each scan, normalized to the cerebellar crus. A combination volume of interest (VOI) = weighted average of parietal, temporal, and occipital regions was used. The protocol pre-specified that test-retest endpoint was to be calculated for the combined group of healthy volunteers and cognitively impaired subjects</description>
        <time_frame>80-100 minutes postdose</time_frame>
        <population>All subjects with a valid test and re-test scan. The 80-100 minute scan was not done for one subject in the healthy volunteer group due to technical difficulties with the scanning apparatus</population>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>All study subjects&#xD;
Flortaucipir F18: IV injection, 370 MBq (10 mCi), two doses up to four weeks apart&#xD;
Brain PET scan: positron emission tomography (PET) scan of the brain</description>
          </group>
        </group_list>
        <measure>
          <title>Test-Retest Reproducibility</title>
          <description>Evaluate test-retest reproducibility of flortaucipir for brain imaging of tau in healthy volunteers and subjects with cognitive impairment. Standard uptake value ratios (SUVRs) for each scan, normalized to the cerebellar crus. A combination volume of interest (VOI) = weighted average of parietal, temporal, and occipital regions was used. The protocol pre-specified that test-retest endpoint was to be calculated for the combined group of healthy volunteers and cognitively impaired subjects</description>
          <population>All subjects with a valid test and re-test scan. The 80-100 minute scan was not done for one subject in the healthy volunteer group due to technical difficulties with the scanning apparatus</population>
          <units>standardized uptake value ratio (SUVr)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Test Imaging</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.342" spread="0.341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retest Imaging</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.355" spread="0.309"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Intraclass correlation coefficient [ICC(2,1)] analysis from Shrout and Fleiss</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>ICC</param_type>
            <param_value>0.971</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.935</ci_lower_limit>
            <ci_upper_limit>0.988</ci_upper_limit>
            <estimate_desc>Assessed the agreement between the test and retest imaging of the combination VOI SUVr</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Test-Retest Reproducibility</title>
        <description>Evaluate test-retest reproducibility of 18F-AV-1451 for brain imaging of tau in healthy volunteers and subjects with cognitive impairment. Standard uptake value ratios (SUVRs) for each scan, normalized to the cerebellar crus. A combination volume of interest (VOI) = weighted average of parietal, temporal, and occipital regions was used. The protocol pre-specified that test-retest endpoint was to be calculated for the combined group of healthy volunteers and cognitively impaired subjects</description>
        <time_frame>110-130 minutes postdose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Subjects</title>
            <description>All study subjects&#xD;
Flortaucipir F18: IV injection, 370 MBq (10 mCi), two doses up to four weeks apart&#xD;
Brain PET scan: positron emission tomography (PET) scan of the brain</description>
          </group>
        </group_list>
        <measure>
          <title>Test-Retest Reproducibility</title>
          <description>Evaluate test-retest reproducibility of 18F-AV-1451 for brain imaging of tau in healthy volunteers and subjects with cognitive impairment. Standard uptake value ratios (SUVRs) for each scan, normalized to the cerebellar crus. A combination volume of interest (VOI) = weighted average of parietal, temporal, and occipital regions was used. The protocol pre-specified that test-retest endpoint was to be calculated for the combined group of healthy volunteers and cognitively impaired subjects</description>
          <units>standardized uptake value ratio (SUVr)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Test Imaging</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.459" spread="0.455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retest Imaging</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.457" spread="0.396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Intraclass correlation coefficient [ICC(2,1)] analysis from Shrout and Fleiss</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>ICC</param_type>
            <param_value>0.968</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.926</ci_lower_limit>
            <ci_upper_limit>0.986</ci_upper_limit>
            <estimate_desc>Assessed the agreement between the test and retest imaging of the combination VOI SUVr</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>End of study for AE reporting was 48 hours after flortaucipir administration at each imaging visit.</time_frame>
      <desc>Adverse Events were defined as occurring or worsening after injection of dose, within 48 hours post injection, at an imaging visit. AEs occurring after study drug administration, but outside that window were not recorded, unless considered attributable to flortaucipir.</desc>
      <group_list>
        <group group_id="E1">
          <title>Healthy Volunteer Subjects</title>
          <description>Healthy males or females 50 years or older with no evidence of cognitive impairment&#xD;
Flortaucipir F18: IV injection, 370 MBq (10 mCi), two doses up to four weeks apart&#xD;
Brain PET scan: positron emission tomography (PET) scan of the brain</description>
        </group>
        <group group_id="E2">
          <title>MCI Subjects</title>
          <description>Subjects 50 years or older with mild cognitive impairment (MCI)&#xD;
Flortaucipir F18: IV injection, 370 MBq (10 mCi), two doses up to four weeks apart&#xD;
Brain PET scan: positron emission tomography (PET) scan of the brain</description>
        </group>
        <group group_id="E3">
          <title>Probable AD Subjects</title>
          <description>Subjects 50 years or older with probable Alzheimer's Disease (AD)&#xD;
Flortaucipir F18: IV injection, 370 MBq (10 mCi), two doses up to four weeks apart&#xD;
Brain PET scan: positron emission tomography (PET) scan of the brain</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1.0</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Avid Radiopharmaceuticals, Inc.</organization>
      <phone>215-298-0700</phone>
      <email>clinicaloperations@avidrp.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

